Abstract. ABCG2 is a multidrug cellular transport protein that is associated with resistance to certain treatments in patients, particularly anticancer treatment. The tumor-protective properties of ABCG2 expression are reported to be a feature of a subset of stem cell-like tumor cells. While protection against chemotherapy has been well analyzed, the role of ABCG2 in the treatment with tyrosine kinase inhibitors is only partially understood. Tyrosine kinase inhibitors are currently the main treatment option in irresectable renal cell carcinomas. To investigate possible underlying sequence variations in the ABCG2 gene with relevance to the functional properties of the protein, 36 patient samples were analyzed. Using sequence analysis and single-nucleotide polymorphism databases, sequence variations in the highly conserved domains of the binding pocket of ABCG2 were analyzed. The resulting variations were used for computational protein prediction algorithms to identify conformational alterations. A relevant shift from A to G at position 1376 (resulting in Y→C at 459 aa) was identified and found to be present in 8.3% of the patients. These patients are currently in follow-up after resection, thus, further analysis will reveal whether this mutation has relevance to treatment efficacy.
Introduction
During the last decades, the development and clinical use of anticancer drugs has become a regularity and therefore an important way of controlling malignancies. However, tumors can develop drug resistance to different therapeutic drugs, making available chemotherapeutic agents ineffective in the course of the disease. Among the proteins involved in anticancer drug resistance are the ATP-binding cassette (ABC) transporters (1). ABC transporters constitute the largest superfamily of human cellular transporters. There are currently 48 members classified in seven subfamilies termed A to G. These transporters have the ability to actively transfer a multitude of structurally dissimilar endogenous and exogenous substrates and their metabolites across cell membranes (2). ABCG2 (also known as the breast cancer resistance protein/mitoxantrone-resistance/ ABC protein) consists of 655 amino acids, one transmembrane domain with six putative transmembrane segments, and a single ATP-binding site. Deduced from its structure, ABCG2 is a 'semi-transporter' (3-5) similar to other members of the ABCG subfamily including the Drosophila White protein ortholog (6) . Overexpression of ABCG2 has been shown to confer resistance to a variety of chemotherapeutic agents. Affected drugs are anthracenedione mitoxantrone (7, 8) ; the camptothecin derivatives, topotecan (9,10) and SN-38 (11); the anthracycline doxorubicin (12) ; and the antifolate methotrexate (13) (14) (15) . Mutations in the ABCG2 gene have been associated with high-level anticancer drug resistance (16) . Furthermore, the effect of tyrosine kinase inhibitors on ABCG2 has been reported (17) . Pharmacogenetic studies showed influences on pharmacokinetics of tyrosine kinase inhibitors through mutations in the ABCG2 coding sequence (18) . The use of the tyrosine kinase inhibitor imatinib has been shown to overcome cancer drug resistance via ABCG2, whereas the efflux function is inhibited by tyrosine kinase inhibitors. This functionality was shown to be mediated through an interaction with ABCG2 at the substrate binding site (19) . Recent structural analyses identified transmembrane domain 3 (around amino acid position 482) as the potential substrate-binding pocket (20) . In medical oncology, tyrosine kinase inhibitors have become important drugs in the treatment of renal cancer and therefore predictive markers for treatment efficacy are of interest. To date, no data on mutations in the potential substrate binding pocket of ABCG2 in tumor tissue are available. Therefore, our aim was to investigate mutations in the coding region for the transmembrane domain 3 and the surrounding domains of ABCG2 in numerous renal cancer samples. Thus, we directly sequenced the corresponding cDNA taken from 36 renal cancer tumor samples. Computational protein secondary structure prediction. To evaluate the impact of an amino acid change we used the JPRED software (http://www.compbio.dundee.ac.uk/www-jpred/) (23) . This software predicts the secondary structure using a neural network called Jnet. The prediction is the definition of each residue into either α helix, β sheet or random coil secondary structures (24, 25) . Predictions were generated for the unaltered protein sequence and for the corresponding mutated protein.
Predictions were then compared by visual inspection. Additionally, a secondary structure prediction was performed with the ESyPred3D program (26), accessible through http://www.fundp.ac.be/sciences/biologie/urbm/ bioinfo/esypred/. A secondary structure could be computed for the unaltered protein, but no secondary structure prediction was possible for the mutated protein.
Results

Comparative proteomics analysis.
To further elucidate the structural organization of the domains in the region of interest, a computational analysis was performed. BLASTp searches and a PSI-BLAST against the whole protein, the ABC_Transporter_2 domain (PS50893) and the ABC2-membrane domain (PF01061) revealed a set of highly conserved residues. In Fig. 1 , the position-specific conservation scores and a subset of aligned protein sequences are shown.
Sequence analysis. Detailed examination of the raw sequences and the automated sequences revealed a heterozygous shift from A to G at position 1376 (Y→C at 459 aa, ICD1a, intracellular domain 1a, a position which is highly conserved) in Association with clinical data. Tumor samples with mutations led to evaluation of the clinical course of the corresponding patient. All 3 patients had surgical resection of the tumor and are in regular follow-up. To date, no active tumor disease has been found in the 3 patients. Therefore, no clinical data on treatment response were available for these patients.
Discussion
Cancer drug resistance is a problem usually encountered in prolonged chemotherapy. A significant proportion of patients has no primary response to certain chemotherapeutic agents. Understanding the mechanisms behind this drug resistance on the molecular level can lead to improved therapeutic approaches. In the case of renal carcinoma, the introduction of tyrosine kinase inhibitors marked the beginning of a new therapeutic era. Thus far, mechanisms for tumor drug resistance against tyrosine kinase inhibitors in renal cancer cells have not been identified.
The ABCG2 gene was identified as a potent 'de-toxification' transporter for tyrosine kinase inhibitors in cancer cells. In renal cancer cell lines, aberrant promoter methylation of the ABCG2 gene was shown (27) and multiple SNPs have been reported in patients with renal cancer (28), but no direct analyis of tumor tissue samples or a direct association with resistance to tyrosine kinase inhibitors has been reported. Herein we report an analysis of the corresponding cDNA sequence of the probable substrate binding pocket of ABCG2 by direct sequencing. It has been hypothesized that residue R482 in the transmembrane domain 3 (TM3) is likely to interact with substrates based on the effect of R482G/T mutations (29) . The aforementioned mutations generated gain-of-function mutants, resulting in resistance to a wider range of substrates than the wild-type transporter.
Further mutagenesis studies showed that replacement of arginine with virtually any residue that was not positively charged led to a similar gain-of-function or change-offunction (30) . Based on these findings, it was speculated that R482 must be part of the substrate-binding pocket in the structure (20) . Our data shows a mutation resulting in Y459C in the intracellular domain 1a (ICD1a). This position was identified as highly conserved (20) and showed heterozygous mutations from A to G at the nucleotide position 1376 in 3 out of 36 tumor samples. Based on the actual models (20) , the apparent flexibility of the ICD1 may play a role in transmitting conformational changes from the nucleotide binding domain to the transmembrane domain or vice versa. The prediction of JPRED regarding secondary folding showed an alteration in the adjacent helical structure supporting the hypothesis of a structural change associated with this mutation.
Two mutation-bearing tumor samples were clear cell renal carcinomas, one sample included a chromophobe renal cell carcinoma, therefore, association of the mutation with a certain histological tumor type was not possible.
In future studies we will investigate tumor tissue from renal cancer patients who receive treatment with tyrosine kinase inhibitors to determine whether this mutation is associated with increased tumor drug resistance or good response to therapy with tyrosine kinase inhibitors.
The estimated rate of 8.3% among all renal cancer patients makes this mutation particularly attractive with regard to a possible pre-estimate of (non-surgical) therapeutic efficacy. This is the first report on the sequence analysis of the substrate binding pocket ABCG2 from tumor tissue of renal cell carcinoma. 
